Robotic surgery utilization & competition — China pressure & Distalmotion/CMR updates
Key Questions
What was the YoY growth in Q4 procedures for robotic surgery?
Q4 procedures grew +19% YoY, with +16% in the US and +24% outside the US. Da Vinci 5 placements rose from 303 to a base of 1,232.
What pressures is Intuitive Surgical facing in China?
China sees intense competition from MicroPort tenders and price wars, with +368% YoY exports favoring local players like MicroPort and Jingfeng. Cathay Haitong notes ISRG's strong position but highlights lower-cost rivals.
What is the projected size of the surgical robotics market?
The market is forecasted at $15.25B to $47.5B by 2033, with 11.3-17.3% CAGR. Intuitive Surgical leads with 51% NA share and over 11,106 installs globally.
What US positives support robotic surgery adoption?
US tailwinds include Southern NH Health adopting da Vinci, gyn dv Xi superiority over laparoscopy, ASC growth, and bariatrics benefits vs GLP-1 drugs, where da Vinci shows advantages amid $10.1B rev and 28% margins.
What updates are there on competitors like Distalmotion and CMR?
Distalmotion's Dexter and CMR's Versius are set for December 2025 updates. Other competitors include Medtronic's Hugo in UK bariatrics, JNJ's Ottava, and Stryker.
How is Restore Robotics impacting da Vinci Xi?
Restore received FDA 510(k) clearances to remanufacture da Vinci Xi instruments, potentially affecting services revenue through cost-competitive alternatives.
What role does da Vinci play in the anti-obesity market?
Da Vinci shows superiority in bariatrics versus GLP-1 drugs, positioning Intuitive Surgical as a dark horse in the massive anti-obesity market despite GLP-1 YTD -20% performance.
What should be monitored in robotic surgery competition?
Key monitors include scaling in cardiac procedures, moat strength, services erosion from remanufacturers, bariatrics growth, and competition in ortho, colorectal, and lung cancer surgeries from players like Stereotaxis and Medtronic.
Q4 procedures +19% YoY (16% US/24% OUS)/dv5 303 to 1,232 base; China pressure MicroPort tenders/price wars +368% YoY exports favoring locals ex-1A8yhTcx/ex-077f9dad/ex-56158c28/CMEF ex-99aa6897 (Cathay Haitong: ISRG 11,106 installs/$10B+ rev/non-US>30%rev/40%installs/23%growth; MicroPort +287% overseas/Jingfeng 60% efficacy lower cost; mkt $23.8B/30k installs 2033)/surg robotics $15.25B-$47.5B 2033 11.3-17.3%CAGR (ISRG#1/NA51% ex-158c5600); U.S. positives: Southern NH Health da Vinci ex-0bba9e37/gyn dv Xi vs lap ex-e61f5fc9/ASC tailwinds ex-b3c69217/bariatrics da Vinci superiority vs GLP-1 ex-9b1659c1 ($451 YTD-20%, $10.1B rev +20%, 28% margins). Comp: Restore da Vinci Xi reman additional high-use 510(k)s ex-1AGyFBlw/935a2ad2/Distalmotion Dexter ex-5b4946d2/CMR Versius Dec'25 ex-19wwffB4/MDT Hugo UK bariatrics/JNJ Ottava ex-a8415d92/ex-52aa7c87/Stryker ex-a5a8f251; ortho AAOS/Stereotaxis Synchrony ex-1AEV3frM/be2cdef5/non-DaVinci colorectal ex-7c528919; lung cancer surgery vs Medtronic/Ethicon ex-5d875c9c. Monitor scaling/cardiac moat/services erosion/bariatrics.